Cognitive decline is a debilitating feature of most neurodegenerative diseases of the central nervous system, including Alzheimer's disease 1 . The causes leading to such impairment are only poorly understood and effective treatments are slow to emerge 2 . Here we show that cognitive capacities in the neurodegenerating brain are constrained by an epigenetic blockade of gene transcription that is potentially reversible. This blockade is mediated by histone deacetylase 2, which is increased by Alzheimer's-disease-related neurotoxic insults in vitro, in two mouse models of neurodegeneration and in patients with Alzheimer's disease. Histone deacetylase 2 associates with and reduces the histone acetylation of genes important for learning and memory, which show a concomitant decrease in expression. Importantly, reversing the build-up of histone deacetylase 2 by short-hairpin-RNA-mediated knockdown unlocks the repression of these genes, reinstates structural and synaptic plasticity, and abolishes neurodegenerationassociated memory impairments. These findings advocate for the development of selective inhibitors of histone deacetylase 2 and suggest that cognitive capacities following neurodegeneration are not entirely lost, but merely impaired by this epigenetic blockade.
Cognitive decline is a debilitating feature of most neurodegenerative diseases of the central nervous system, including Alzheimer's disease 1 . The causes leading to such impairment are only poorly understood and effective treatments are slow to emerge 2 . Here we show that cognitive capacities in the neurodegenerating brain are constrained by an epigenetic blockade of gene transcription that is potentially reversible. This blockade is mediated by histone deacetylase 2, which is increased by Alzheimer's-disease-related neurotoxic insults in vitro, in two mouse models of neurodegeneration and in patients with Alzheimer's disease. Histone deacetylase 2 associates with and reduces the histone acetylation of genes important for learning and memory, which show a concomitant decrease in expression. Importantly, reversing the build-up of histone deacetylase 2 by short-hairpin-RNA-mediated knockdown unlocks the repression of these genes, reinstates structural and synaptic plasticity, and abolishes neurodegenerationassociated memory impairments. These findings advocate for the development of selective inhibitors of histone deacetylase 2 and suggest that cognitive capacities following neurodegeneration are not entirely lost, but merely impaired by this epigenetic blockade.
Long-lasting forms of memories require stable gene expression changes 3 , which are in part orchestrated by chromatin-templated epigenetic processes 4 . Of the epigenetic modifications identified so far in the nervous system, histone acetylation has been unequivocally associated with facilitating learning and memory 4 . Acetylation diminishes the electrostatic affinity between neighbouring histones and the DNA and, consequently, can promote a more open chromatin structure that allows for memory-related gene transcription 5 .
Over the past decade, several studies have reported sporadic cases of reduced histone acetylation in animal models of neurodegeneration that are characterized by cognitive decline, including models of Alzheimer's disease 4 . Accordingly, pharmacological treatments aimed at increasing histone acetylation have shown promising results in reversing cognitive deficits in some of these models, predominantly by the use of nonselective histone deacetylase (HDAC) inhibitors 6 . However, the causative agent of such memory-impairing histone acetylation changes, and, hence, the best targets for pharmacological strategies, remain unknown. One likely candidate is HDAC2, a class I HDAC that negatively regulates memory and synaptic plasticity in the healthy mouse brain 7, 8 .
To investigate whether HDAC2 mediates cognitive deficits associated with neurodegeneration, we measured its abundance in CK-p25 mice 9, 10 , which inducibly and forebrain-specifically overexpress p25, a truncated version of p35. p25 aberrantly activates cyclin-dependent kinase 5 (CDK5), and is implicated in various neurodegenerative diseases 11 , including Alzheimer's disease 12 . After 6 weeks of p25 induction, CK-p25 mice display Alzheimer's-disease-related pathologies such as neuronal loss 9 , b-amyloid accumulation 10 , reactive astrogliosis 9 and reduced synaptic density 13 , most prominently in the hippocampus and the cortex, two brain areas important for memory formation and storage, respectively 14 . Accordingly, 6-week-induced CK-p25 (hereafter referred to as CK-p25) mice also display spatial and associative memory deficits 13 .
Using immunohistochemistry and western blot analysis, we found that HDAC2 was significantly increased in neuronal nuclei in hippocampal area CA1 in CK-p25 mice compared with control littermates (Fig. 1a , d, e; see Supplementary Fig. 2a for a specificity control for the HDAC2 signal). No changes in HDAC2 were observed in hippocampal area CA3 or the dentate gyrus ( Supplementary Fig. 3a , b), explaining the overall marginal increase in the entire hippocampus. Interestingly, this effect appears to be non-cell-autonomous, as both p25-positive and p25-negative cells displayed elevated HDAC2 (Fig. 1a ). In contrast, levels of the structurally highly related HDAC1, and of HDAC3, another class I HDAC involved in memory formation 15 , were not changed ( Fig. 1b, c, e ). Furthermore, HDAC2, but not HDAC1 or HDAC3, was also increased in the prefrontal cortex of CK-p25 mice ( Supplementary Fig. 4 ), whereas in the amygdala, a brain area not affected by neurodegeneration in the CK-p25 mice, its levels remained unchanged ( Supplementary Fig. 3c ). This neurodegeneration-associated increase of HDAC2 was confirmed in another mouse model of Alzheimer's-disease-related pathologies and cognitive decline, the 5XFAD mouse 16, 17 ( Supplementary Fig. 5 ).
Next, we aimed to determine the functional consequences of elevated HDAC2. Because HDAC2 has been shown to associate with the promoter region of genes involved in memory and synaptic plasticity 7 , we proposed that it is enriched at these genes following neurodegeneration. Of the known HDAC2 targets 7 , we focused on those that, in several independent studies, had been demonstrated to be downregulated in the human brain with Alzheimer's disease (Supplementary Table 1 ). These include the immediate-early genes Arc, Bdnf exons I, II and IV, Egr1, Homer1, and Cdk5, implicated in learning and memory, and genes related to synaptic plasticity such as the glutamate receptor subunits GluR1, GluR2, NR2A and NR2B (also known as Gria1, Gria2, Grin2a and Grin2b), as well as Nfl (neurofilament light chain, also known as Nefl), Syp (synaptophysin) and Syt1 (synaptotagmin 1). Using chromatin immunoprecipitation (ChIP, for primers see Supplementary  Table 2 ), we found that HDAC2 is significantly enriched at these genes in the CK-p25 hippocampus, the exception being the promoter regions of the activity-dependent Bdnf exons I and II 18 , and the housekeeping genes b-actin, b-globin and b-tubulin ( Fig. 1f ). In contrast, binding of HDAC1 and HDAC3 was unaltered ( Supplementary Fig. 6a, b ). Interestingly, in agreement with previous reports showing that HDAC2 can also bind to a gene's coding region 19 , we also found HDAC2 more abundantly bound to the coding sequence of the same genes (see Supplementary Fig. 7 and Supplementary Table 3 for primer sequences).
We next assessed the acetylation of several histone (H) residues in the promoter region of these genes, for which acetylation has been shown to be important for learning, memory, and synaptic plasticity, such as H2B lysine (K) 5, H3K14, H4K5 and H4K12 (ref. 4) . ChIP analyses revealed a hypoacetylation for all residues at the neuroplasticity genes ( Fig. 1g and Supplementary Fig. 6c -e), albeit to different extents. Importantly, the acetylation of housekeeping genes was not altered. The effects of elevated HDAC2 levels further appear to be restricted to histones, as we found no overall acetylation changes on other proteins regulated by this modification, such as tau (also known as MAPT), protein 53 (p53; also known as TP53) and tubulin, nor in overall nuclear or cytoplasmic protein acetylation ( Supplementary Fig. 8 ).
Next, to determine the functional consequences of promoter hypoacetylation, we assessed the binding of activated (that is, phosphorylated) RNA polymerase II (RNA Pol II), and found it to be markedly reduced ( Fig. 1h ). This prompted us to measure the messenger RNA (mRNA) expression of these genes by quantitative reverse-transcription PCR (RT-PCR) (primers in Supplementary Table 4 ). We found reduced expression for all genes with elevated HDAC2 binding and a concomitant decrease in histone acetylation and RNA Pol II binding ( Fig. 1i ). Of note, HDAC2 probably acts with the transcriptional repressor complexes CoREST, NuRD and SIN3, as we found increased association of HDAC2 with these complexes in hippocampal CK-p25 extracts by co-immunoprecipitation ( Supplementary Fig. 9 ). Taken together, these results indicate that HDAC2 mediates a local chromatin compaction of neuroplasticity genes, which decreases their expression and may contribute to cognitive decline during neurodegeneration.
To examine causally such a possibility, we generated adeno-associated viral vectors carrying either short-hairpin RNAs (shRNAs) directed against HDAC2 or scrambled control shRNAs ( Supplementary 
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10a, b). The knockdown efficiency of the shRNAs in culture was about 25-30% ( Supplementary Fig. 10c -f), ideally suited for the targeted normalization of the 20-50% increase of HDAC2 in the CK-p25 mice. We injected these vectors bilaterally into hippocampal area CA1 of 2-weekinduced CK-p25 and control mice, and assessed HDAC2 levels 4 weeks after viral injection ( Supplementary Fig. 10g ). CK-p25 animals injected with an shRNA against HDAC2 (CK-p25, shHDAC2) showed reduced HDAC2 levels compared with CK-p25 animals injected with control scrambled shRNA (CK-p25, scr), indistinguishable from control mice injected with scrambled shRNA (CON, scr) ( Fig. 2a, b ). Protein levels of HDAC1 and HDAC3 remained unchanged ( Supplementary Fig. 11 ). We observed transduction efficiencies of 53-61% (mean 6 s.e.m. 57.4 6 2.5; n 5 3-4 mice per group analysed) and comparable infection rates in both control and CK-p25 hippocampi ( Supplementary Fig. 10h ).
Next, we sought to determine whether reducing HDAC2 levels would alter the promoter histone acetylation and mRNA expression of neuroplasticity genes. We found that H4K12 acetylation was significantly enhanced on most of these genes, and they showed increased expression ( Fig. 2c, d) . Importantly, most of these genes showed comparable, or even higher, expression in CK-p25, shHDAC2 mice compared with CON, scr animals (black dotted lines).
Based on these findings, we investigated whether such regained chromatin and transcriptional plasticity might translate into morphological and physiological changes in the surviving neurons. To this end, we measured synaptic density by SYP immunohistochemistry, labelling the presynaptic terminals of functional synapses, and dendritic abundance by microtubule-associated protein 2 (MAP2) immunoreactivity. We found that, whereas SYP and MAP2 levels were reduced in the stratum radiatum of CK-p25, scr animals (as previously described for CK-p25 mice 13, 20 ) , their abundance was markedly increased in CK-p25, shHDAC2 animals, to levels comparable to CON, scr animals ( Fig. 2e-g) . Interestingly, however, the number of surviving neurons, as evidenced by NeuN immunohistochemistry, was not altered by HDAC2 reduction ( Supplementary Fig. 12 ). Next, we measured synaptic plasticity by electrophysiological recordings and observed that long-term potentiation in CA1 neurons was undistinguishable between CK-p25, shHDAC2 and CON, scr animals, but significantly improved over CK-p25, scr animals. A similar effect was observed for basal synaptic plasticity ( Supplementary  Fig. 13 ). Together, these data indicate that, although HDAC2 normalization did not impact neuronal survival, it did reinstate morphological and synaptic plasticity in the surviving neurons.
We suggested that the reduction of HDAC2 would also counteract the cognitive deficits associated with neurodegeneration. For this, we assessed associative and spatial memory on a fear-conditioning and water maze task, respectively, two types of hippocampus-dependent memory that are severely perturbed in CK-p25 animals 13 . We observed 
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that associative memory of CK-p25, shHDAC2 animals returned to levels of CON, scr animals ( Fig. 2h) . Likewise, CK-p25, shHDAC2 animals showed significantly reduced escape latencies compared with CK-p25, scr animals during training in the water maze ( Fig. 2i ) and, 24 h later, they spent significantly more time in the target quadrant, indistinguishable from the performance of CON, scr mice ( Fig. 2j ). Overall, swimming behaviour was similar between the different groups ( Supplementary Fig. 14a, b) , and altering HDAC2 levels per se did not affect locomotor activity or anxiety as assessed by an open field test ( Supplementary Fig. 14c-f ). Together, these results indicate that elevated HDAC2 levels are causally involved in the cognitive decline associated with neurodegeneration in CK-p25 mice, but that the prevention of HDAC2 upregulation rescues memory capacities.
To gain insight into the mechanisms underlying the increase in HDAC2, we exposed primary hippocampal neurons to neurotoxic stimuli characteristic of Alzheimer's-disease-related neurodegeneration, hydrogen peroxide (H 2 O 2 ) and amyloid-b oligomers 21, 22 . As revealed by immunocytochemistry and western blot analysis, treatment with either H 2 O 2 or amyloid-b 1-42 , but not control amyloidb 42-1 , oligomers was sufficient to increase HDAC2 ( Fig. 3a-d , left panels, and Supplementary Fig. 15a-d) . Importantly, both neurotoxic stimuli increased Hdac2 at the mRNA level (Fig. 3e ), and increased Hdac2 transcription was also evident in the CK-p25 hippocampus ( Fig. 3f ), suggesting the involvement of transcriptional mechanisms.
This prompted us to screen the Hdac2 promoter for potential binding sites of transcriptional regulators. Using transcription factor binding databases 23 , we found a well-conserved recognition element for the glucocorticoid receptor 1 (GR1, also known as NR3C1) in the proximal promoter region of Hdac2 (Fig. 3g ). Glucocorticoid receptors are activated by phosphorylation following behavioural or cellular stress and, upon binding to the glucocorticoid responsive element (GRE) in a gene's promoter region, they can act as transcriptional activators or repressors, depending, in part, on the residue phosphorylated 24 . Of its known phosphorylation sites, serine (S) 211 has been robustly associated with activated forms of GR1 (ref. 25) .
Based on this knowledge, we examined whether S211 phosphorylation on GR1 was increased after neurotoxic insults in vitro, and in the CK-p25 brain in vivo. Immunocytochemical labelling and western blot analysis of cultured hippocampal neurons following H 2 O 2 and amyloid-b 1-42 treatment revealed a significantly increased phosphorylation of GR1 (pGR1) on S211 compared with control conditions ( Fig. 3a-d , middle panels, and Supplementary Fig. 15a-d ; see Supplementary Fig. 2b for anti-pGR1 S211 specificity). Furthermore, the CK-p25 hippocampus showed similarly increased pGR1 levels (Fig. 3h, i and Supplementary Fig. 16 ). Remarkably, we observed that the increase in pGR1 occurred concurrently with that of HDAC2 following neurotoxicity (Fig. 3a , c, i, j) and, using forebrain extracts of conditional Cdk5 knockout (Cdk5cKO) and control mice 26 , we identified CDK5 as a GR1 kinase in vivo (Fig. 3k ).
We then sought to determine whether GR1 phosphorylation increases Hdac2 transcription. We first examined the binding of pGR1 to the Hdac2 promoter by pGR1-ChIP and primer pairs (Supplementary Table 2 ) spanning a region from 21000 to 1300 base pairs around the Hdac2 transcriptional start site (Fig. 3l, top) . We found that pGR1 binding to the Hdac2-GRE was significantly increased in the CK-p25 hippocampus (Fig. 3l, bottom) . Similar results were obtained after amyloid-b 1-42 treatment of primary hippocampal cultures (Supplementary Fig. 15e ). Second, to determine whether GR1 is directly capable of transcriptionally activating Hdac2, we cloned the Hdac2 promoter with and without the GRE into a luciferase construct and tested its activity in CAD cells, a primary neuron-like cell line. We found that the presence of the GRE alone increased the luciferase activity by approximately threefold but that, upon the addition of a constitutively active form of glucocorticoid receptor, GR526 (see Methods), this activity was further doubled. However, without the Hdac2-GRE, the addition of GR526 had no effect ( Supplementary Fig. 17 ). Importantly, we found that the Hdac2-GRE also responds to neurotoxic stimuli. When CAD cells were treated with either H 2 O 2 or amyloid-b 1-42 , luciferase activity was significantly increased, but only with the GRE present ( Fig. 3m , orange bars). Furthermore, the capability of GR to activate Hdac2 critically depends upon its phosphorylation. When S211 was mutated to alanine (GR S211A ), the glucocorticoid receptor was no longer capable of activating Hdac2 in vitro (Fig. 3n ). This dependency on S211 phosphorylation also occurs in vivo, as Cdk5cKO forebrain extracts 26 had reduced pGR1 and HDAC2 levels (Fig. 3k) . Taken together, these results indicate that Alzheimer's-disease-related neurotoxic stimuli lead to an increase in Hdac2 gene transcription by mechanisms involving glucocorticoid receptor activation and its interaction with the Hdac2-GRE.
Lastly, to assess the relevance of these findings in humans, we compared HDAC2 abundance in post-mortem brain samples from patients with varying degrees of non-familial Alzheimer's disease, the most common form of neurodegeneration-associated dementia worldwide 27 . The cases used here (Supplementary Table 5 ) are defined by the Braak and Braak stages 28 , which are characterized by the accumulation of hyperphosphorylated tau protein in the cortices (Supplementary Fig. 18 ), and by increasing neurodegeneration 28 and cognitive impairment 29 . We found that, in all Alzheimer's-diseaserelated Braak and Braak stages, HDAC2 levels were significantly elevated in hippocampal area CA1 (Fig. 4a, d ) and the entorhinal cortex ( Supplementary Fig. 19a, d) , which are among the earliest and most affected brain areas in Alzheimer's disease 2 and crucial for memory formation and storage 14 . HDAC2 accumulation was visible beginning 
LETTER RESEARCH
at Braak and Braak stage I/II, implicating it as an early event in the progression of Alzheimer's disease. In contrast, levels of HDAC1 and HDAC3 were not altered (Fig. 4b, c , e, f and Supplementary Fig. 19b, c , e, f). Thus, elevated levels of HDAC2 may also accompany the cognitive decline of the human neurodegenerating brain.
The findings presented in this study describe that epigenetic mechanisms substantially contribute to the cognitive decline associated with Alzheimer's disease-related neurodegeneration. Although it is well documented that neuronal loss and amyloid-b-or tau-induced neurotoxicity acutely disable synaptic functions, in turn leading to cognitive deficits 1,2,30 , the HDAC2-mediated epigenetic blockade of neuroplasticity-related gene expression could delineate a process by which memory functions become permanently impaired in the Alzheimer's disease brain ( Supplementary Fig. 1a) . This blockade appears to be induced by GR1; thus, glucocorticoid receptors may function as molecular mediators between neurodegeneration-associated neurotoxic stressors and cognitive impairment ( Supplementary Fig. 1b) .
Intriguingly, our findings may also provide a potential explanation, at least in part, as to why, in some clinical trials, cognitive impairments in patients with Alzheimer's disease persist despite successful amyloid-b clearance 2 : once the epigenetic blockade is in place, reducing amyloid-b generation and deposition alone may not be sufficient to rescue against cognitive dysfunction. A more efficacious strategy may therefore lie in the combination of amyloid-b reduction with the inhibition of HDAC2. By extension, these findings pinpoint HDAC2 as the probable target of non-selective HDAC inhibitors that counteract cognitive decline in mouse models of Alzheimer's disease 6 and, as a result, strongly advocate for the development of HDAC2-selective inhibitors. Finally, our finding that HDAC2 inhibition probably reinstates transcriptional, morphological and synaptic plasticity in the surviving neurons of the neurodegenerating brain raises hope that such plasticity is not irrevocably lost, but merely constrained by the epigenetic blockade.
METHODS SUMMARY
Please refer to Methods for more detail. Human material was used with informed consent from all donors, and all mouse work was approved by the Committee for Animal Care of the Division of Comparative Medicine at the Massachusetts Institute of Technology.
METHODS
Human material. Human material was obtained from the Massachusetts Alzheimer Disease Research Center at Massachusetts General Hospital (protocol number 2004-P-001613/4) and from the Boston Medical Center (H-24454) with informed consent by all donors. The cases analysed in this study are strictly defined according to the Braak and Braak staging 28 , with control cases being brains completely devoid of tau pathologies (Braak and Braak stage 0) 38 . Hippocampal blocks (at the level of the lateral geniculate nucleus) were fixed in paraformaldehyde, paraffin-embedded and sectioned at 10 mm thickness. After antigen retrieval (Biogenex), brain slices were rehydrated using xylene/ethanol, blocked with 5% milk serum in TBS (pH 7.4) at room temperature and incubated at 4 uC overnight in TBS containing 5% milkserum in the following antibodies: amyloid-b, tau (Dako), HDAC1, HDAC2 (Abcam) or HDAC3 (Santa Cruz). Next, they were washed in PBS (pH 7.4), incubated in HRP-conjugated secondary antibodies (Biogenex) and visualized with DAB (Biogenex). Slides were counterstained with haematoxylin and dehydrated with ethanol/xylene. Images were quantified by an experimenter blind to Braak and Braak stages using ImageJ 1.42q. Animal models. All mouse work was approved by the Committee for Animal Care of the Division of Comparative Medicine at the Massachusetts Institute of Technology. Adult (3-6 months old) male double transgenic CK-p25 mice 9,10,13 , 6-month-old male transgenic 5XFAD mice 16 , and 3-to 4-month-old Cdk5cKO mice 26 and their respective control littermates were used for the experiments unless otherwise noted; for CK-p25 mice, all behavioural experiments took place between 6 and 8 weeks of p25 induction, the time when cognitive deficits are first visible 13 . Behavioural experiments were conducted blindly and essentially as described 13 . Open field behaviour was monitored using the VersaMax system (Accuscan) for 20 min. For fear conditioning, mice were put in the conditioning chamber (TSE systems) for 3 min, after which they received a one-time 2 s footshock (0.8 mA). Animals were then left in the box for another 30 s. Twentyfour hours later, the mice were put into the same box and their freezing behaviour was scored during 3 min. For the water maze that took place in a round tank (1.2 m in diameter) filled with white opaque water, mice were first habituated to the task, with the platform being visible for two trials. During habitation and the acquisition phase, mice were allowed to swim for 60 s or until they reached the platform (monitored by HVS Image). Animals that did not reach the platform after 60 s were gently guided towards it; all animals were allowed to remain on the platform for 15 s. For testing, mice were put back into the water without the platform 24 h after that last training session, from a starting position different of the last starting position during the acquisition phase, and their time spent in each quadrant was recorded (HVS Image). Electrophysiology. To record field excitatory postsynaptic potentials, transverse hippocampal slices were prepared from CON, scr, CK-p25, scr and CK-p25, shHDAC2 mice. In brief, the brain was rapidly removed and transferred to icecold, oxygenated (95% O 2 and 5% CO 2 ) cutting solution containing 211 mM sucrose, 3.3 mM KCl, 1.3 mM NaH 2 PO 4 , 0.5 mM CaCl 2 , 10 mM MgCl 2 , 26 mM NaHCO 3 and 11 mM glucose. Hippocampal slices were cut with a VT1000S vibratome (Leica) and transferred for recovery to a holding chamber containing oxygenated artificial cerebrospinal fluid consisting of 124 mM NaCl, 3.3 mM KCl, 1.3 mM NaH 2 PO 4 , 2.5 mM CaCl 2 , 1.5 mM MgCl 2 , 26 mM NaHCO 3 and 11 mM glucose at 28-30 uC for at least 1 h before recording. CA1 field potentials evoked by Schaffer collateral stimulation were measured. After recording of a stable baseline (at least 20 min), long-term potentiation was induced by four episodes of theta burst stimulation (TBS) with 10 s intervals. TBS consisted of ten bursts (each with four pulses at 100 Hz) of stimuli delivered every 200 ms. Recordings were performed using an AM-1800 microelectrode amplifier (A-M systems) and a Digidata 1440A analogue to digital converter (Axon Instruments). All data were digitized and analysed by the use of pClamp10 software (Axon Instruments). Basal synaptic input/output relationship was obtained by plotting field excitatory postsynaptic potential slopes against stimulation intensities. All experiments were performed by an experimenter blind to treatment groups. In vitro studies. Primary mouse hippocampal neuronal cultures (days in vitro [14] [15] [16] [17] were treated with sense and antisense amyloid-b oligomers (1 mM, Bachem) for 24 h or H 2 O 2 (50 mM, Mallinckrodt Chemicals, removed after 5 min, and assessed 8 h later) unless otherwise noted. For ChIP experiments, cortical cultures (days in vitro 10-14) were used.
Dual luciferase assays were conducted on CAD cells 31 (ATCC) that were transfected using lipofectamine (Invitrogen) with 0.5 mg of the proximal promoter region of Hdac2 containing the GRE consensus sequence (CAAGAAGAAAGTG GCTAC) or with the proximal promoter region without the GRE sequence subcloned into the pGL3 reporter vector (Promega) according to the manufacturer's instructions. Cells were cotransfected with 0.05 mg of the constitutively active form of GR 32 , GR526 or GR S211A , and treated with 1 mM amyloid-b 1-42 oligomers or with 50 mM H 2 O 2 .
For site-directed mutagenesis, the complementary DNA for the full-length human glucocorticoid receptor (Addgene) was used and serine 211 was replaced by alanine using the QuikChange Lightning Kit (Agilent Technologies) as per the manufacturer's instructions. All constructs were verified by sequencing (Genewiz). The following mutagenesis primers were used: 59-GTAAAGAGA CGAATGAGGCTCCTTGGAGATCAGACC-39 (forward); 59-GGTCTGATCT CCAAGGAGCCTCATTCGTCTCTTTAC-39 (reverse). Immunohistochemistry and immunocytochemistry. Immunocytochemistry and mouse immunohistochemistry were performed as described 7 . Immunocytochemistry and immunohistochemistry on different experimental conditions were performed with the same antibody solution at the same time to assure identical staining conditions. A negative (that is, no antibody) control was included simultaneously. In brief, for immunohistochemistry, mice were perfused with 10% paraformaldehyde under deep anaesthesia (ketamine, xylazine) and their brains sectioned at 0.35 mm thickness using a vibratome (Leica). For immunocytochemistry, cells were fixed using 4% paraformaldehyde. Slices/cells were permeabilized with 0.1% Triton X-100, blocked and incubated overnight with 0.1% Triton X-100/10% fetal bovine serum in PBS containing primary antibodies: HDAC1, HDAC2 (Abcam), HDAC3 (Santa Cruz), phospho-GR1 (S211) (Cell Signaling), GR (Abcam) or GFP (Aves Labs). Primary antibodies were visualized with Alexa-Fluor 488, Cy3 and Cy5 antibodies (Molecular Probes), neuronal nuclei with Hoechst 33342 (Invitrogen). Note that for staining of shRNA-injected animals, mCherry was visualized without staining, and only Cy2 and Cy5 secondary antibodies were used. Images were acquired using a confocal microscope (LSM 510, Zeiss) at identical settings at the highest intensity for each of the conditions. Images were quantified using ImageJ 1.42q by an experimenter blind to treatment groups, whenever possible. For each experimental condition, 20-40 representative cells per section were analysed, and the mean signal intensity was measured. To assess the specificity of the HDAC2 immunostaining, adult HDAC2 2/2 mice were used as previously described 7 . For a specificity control of the pGR1 antibody, calf intestine phosphatase (CIP) (New England Biolabs) treatment on immunocytochemistry slides was performed as described previously 33 . Calf intestine phosphatase or H 2 O were applied for 40 min in Buffer 3 (New England Biolabs). Molecular analyses. Western blots, co-immunoprecipitation, ChIP and gene expression analyses were performed as described elsewhere 34 with the following modifications, and expressed as fold change of the respective control conditions. For western blots, proteins were extracted using 13 RIPA buffer containing proteinase (complete, Roche) and phosphatase inhibitors (1 mM b-glycerophosphate, 10 mM NaF, 0.1 mM Na 3 VO 4 ), transferred onto PVDF membranes (Biorad) and stripped using stripping buffer (Thermo Scientific). The following primary antibodies were used: acetyl-K (Cell Signaling), aand b-tubulin, b-actin (Sigma), Cdk5 (Santa Cruz), HDAC1, HDAC2 (Abcam), HDAC3, phospho-GR1 (S211) (Cell Signaling), GR1 (Abcam), p53 (Cell Signaling) or tau (Invitrogen). Secondary antibodies were horseradish peroxidase-linked (GE Healthcare). Signal intensities were quantified using ImageJ 1.42q and normalized to values of b-actin, aor b-tubulin. Phospho-GR1 was first normalized to GR1. Three to eight animals were used per condition. Cytoplasmic and nuclear fractionation was performed as described elsewhere 34 .
For co-immunoprecipitation, hippocampal lysates were incubated with HDAC2 (Abcam) or IgG (Sigma) and the immunoprecipitated extracts probed for SIN3A, MTA2 (Abcam), CoRest (Millipore), LSD1 (Cell Signaling) or HDAC2. Signal intensities were quantified using ImageJ 1.42q, and normalized to input. Three or four animals were used per condition.
For ChIP, tissue samples were homogenized in cell lysis buffer containing proteinase (complete, Roche) and phosphatase inhibitors (1 mM b-glycerophosphate, 10 mM NaF, 0.1 mM Na 3 VO 4 ) and chromatin was sonicated using a Branson Digital Sonifier with 10 rounds of 15 s at 25% power per sample on ice to 200-400 base pairs in length. For ChIP of primary cortical cultures, approximately 1 3 10 6 cells were crosslinked in 37% formaldehyde (Sigma), quenched with 203 glycine (Sigma), washed with PBS and cell lysis buffer containing both phosphatase and proteinase inhibitors (Roche) and sonicated in nuclear lysis buffer using a Vibra Cell Sonifier with 3 3 3 pulses of 5 s at 35% power (50% duty) on ice. Sheared chromatin was immunoprecipitated with antibodies against HDAC1, HDAC2 (Abcam), HDAC3 (Santa Cruz), acetyl H2BK5, acetyl H3K14 (Abcam), acetyl H4K5, acetyl H4K12 (Millipore), phospho-GR1 (S211) (Cell Signaling) or phospho-RNA Pol II (Abcam). DNA was extracted by phenol/ chloroform/isoamyl alcohol (American Bioanalytical) and subjected to quantitative PCR (Bio-Rad Thermal Cycler) using primers specific to the promoter or coding regions of the genes assayed (see Supplementary Tables 2 and 3 for primer sequences). The fluorescent signal of the amplified DNA (SYBR green, Bio-Rad) was normalized to input. Four to eight samples were used per condition.
For gene expression analysis, mRNA was extracted (Qiagen), reversetranscribed (Invitrogen) and quantitatively amplified on a thermal cycler LETTER RESEARCH
